(Q48487432)

12 February 2018

title

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. (English)

1 reference

12 February 2018

chronic obstructive pulmonary disease

main subject

0 references

4

Claus Vogelmeier

1 reference

12 February 2018

author name string

Peter Kardos

series ordinal

1

1 reference

12 February 2018

Marion Wencker

series ordinal

2

1 reference

12 February 2018

Thomas Glaab

series ordinal

3

1 reference

12 February 2018

language of work or name

English

0 references

publication date

19 October 2006

1 reference

12 February 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

12 February 2018

volume

175

1 reference

12 February 2018

page(s)

144-149

1 reference

12 February 2018

issue

2

1 reference

12 February 2018

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Update in chronic obstructive pulmonary disease 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Economic analysis of the Confronting COPD survey: an overview of results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Toward a consensus definition for COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Effects of salmeterol on cilia and mucus in COPD and pneumonia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Hypertension in the elderly. Implications and generalizability of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Exacerbations and time spent outdoors in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200602-244OC

10.1164/RCCM.200602-244OC

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

17053207

1 reference

12 February 2018